Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes

Serum fibroblast growth factor 21 levels in patients with mitochondrial diabetes might be much higher than in those with other diabetes types. The results of this study could lead to the establishment of a simple method for screening mitochondrial diabetes using peripheral blood serum.[Image: see te...

Descripción completa

Detalles Bibliográficos
Autores principales: Komorita, Yuji, Shiroozu, Akiyo, Nakamura, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360381/
https://www.ncbi.nlm.nih.gov/pubmed/37246726
http://dx.doi.org/10.1111/jdi.14030
_version_ 1785076092733751296
author Komorita, Yuji
Shiroozu, Akiyo
Nakamura, Hidetoshi
author_facet Komorita, Yuji
Shiroozu, Akiyo
Nakamura, Hidetoshi
author_sort Komorita, Yuji
collection PubMed
description Serum fibroblast growth factor 21 levels in patients with mitochondrial diabetes might be much higher than in those with other diabetes types. The results of this study could lead to the establishment of a simple method for screening mitochondrial diabetes using peripheral blood serum.[Image: see text]
format Online
Article
Text
id pubmed-10360381
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103603812023-07-22 Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes Komorita, Yuji Shiroozu, Akiyo Nakamura, Hidetoshi J Diabetes Investig Letter to the Editor Serum fibroblast growth factor 21 levels in patients with mitochondrial diabetes might be much higher than in those with other diabetes types. The results of this study could lead to the establishment of a simple method for screening mitochondrial diabetes using peripheral blood serum.[Image: see text] John Wiley and Sons Inc. 2023-05-29 /pmc/articles/PMC10360381/ /pubmed/37246726 http://dx.doi.org/10.1111/jdi.14030 Text en © 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Letter to the Editor
Komorita, Yuji
Shiroozu, Akiyo
Nakamura, Hidetoshi
Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes
title Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes
title_full Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes
title_fullStr Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes
title_full_unstemmed Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes
title_short Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes
title_sort fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360381/
https://www.ncbi.nlm.nih.gov/pubmed/37246726
http://dx.doi.org/10.1111/jdi.14030
work_keys_str_mv AT komoritayuji fibroblastgrowthfactor21asacandidateofanovelserumbiomarkerformitochondrialdiabetes
AT shiroozuakiyo fibroblastgrowthfactor21asacandidateofanovelserumbiomarkerformitochondrialdiabetes
AT nakamurahidetoshi fibroblastgrowthfactor21asacandidateofanovelserumbiomarkerformitochondrialdiabetes

Ejemplares similares